Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.
Bacterially synthesised human granulocyte colony-stimulating factor (G-CSF) was administered to patients with advanced cancer. The immediate effect of G-CSF was a fall in the level of circulating neutrophils followed by a rise after 4 hours that was sustained during G-CSF administration. The rise in neutrophil level was less in patients who had been treated previously with chemotherapy and/or radiotherapy. G-CSF was also administered to patients following melphalan and this resulted in a reduction in the duration of the neutropenia that invariably follows melphalan. G-CSF was well tolerated and did not have to be stopped in any patient.
Morstyn
G
G
Clinical Research Programme, Melbourne Tumour Biology Branch, Ludwig Institute for Cancer Research, Australia.
Campbell
L
L
Dührsen
U
U
Souza
L M
LM
Alton
N K
NK
Villeval
J L
JL
Nicola
N A
NA
Boyd
A W
AW
Kannourakis
G
G
Cebon
J
J
D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D008962:Models, Theoretical; D009369:Neoplasms / Q000188:drug therapy*; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use*
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D008558:Melphalan